J & J ’s COVID-19 Vaccine Will Enter Phase 3 Testing, the Fourth To Reach That Stage
Johnson & Johnson announced today (Sept. 23) that it is launching a large-scale Phase 3 test of its COVID-19 vaccine candidate, which was developed based on science supported by the National Institutes of Health. The vaccine, being tested through the company’s Janssen Pharmaceuticals arm, will be the fourth to enter late stage studies, following candidates from Moderna, Pfizer-BioNTech and AstraZeneca. Unlike those vaccine candidates, which all require two shots, J&J’s vaccine involves a single injection. That means it could require half the number of doses to immunize the same number of people. J&J...
Source: TIME: Health - September 23, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Johnson & Johnson ’ s Coronavirus Vaccine Enters Phase 3 Trial With Beth Israel
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p1").init({"mcp":"cbs","width":"100%","height":"100%","video":"4730668","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p1","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 23, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Beth Israel Deacones Medical Center Coronavirus Johnson & Johnson Source Type: news

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen ’s COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., September 23, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development. These results have been submitted to medRxiv and are due to be published online i...
Source: Johnson and Johnson - September 23, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Who Should Receive the New Ebola Vaccine? Who Should Receive the New Ebola Vaccine?
While the world waits for an effective COVID vaccine, let's not overlook the vaccine now available for an even deadlier disease.Medscape Internal Medicine (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - September 22, 2020 Category: Infectious Diseases Tags: Infectious Diseases Commentary Source Type: news

The Great Vaccine Race: Inside the Unprecedented Scramble to Immunize the World Against COVID-19
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - September 10, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Magazine Source Type: news

Biopharma Leaders Unite To Stand With Science
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the un...
Source: Johnson and Johnson - September 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Navigating Safely Through The Pandemic
By Stephen LeahySep 2 2020 (IPS-Partners) Having reported on SARS, Ebola, Bird Flu (H5N1) outbreaks, as well as writing about efforts to combat HIV, I was horrified by what was going on in Wuhan, China last Jan mainly because of how fast this new SARS-CoV-2 virus spread. By early Feb it seemed likely there’d be a global pandemic and by the end of Feb I started to freak out as the pandemic took hold. I’ve never been to Wuhan or China nor seen anyone who had; and I hadn’t travelled any where recently. It was nearly impossible for me to have encountered the virus but that didn’t keep me from getting si...
Source: IPS Inter Press Service - Health - September 2, 2020 Category: International Medicine & Public Health Authors: Stephen Leahy Tags: Health Humanitarian Emergencies Source Type: news

Exclusive: The Scientist Who Sequenced the First COVID-19 Genome Speaks Out About the Controversies Surrounding His Work
Over the past few years, Professor Zhang Yongzhen has made it his business to sequence thousands of previously unknown viruses. But he knew straight away that this one was particularly nasty. It was about 1:30 p.m. on Jan. 3 that a metal box arrived at the drab, beige buildings that house the Shanghai Public Health Clinical Center. Inside was a test tube packed in dry ice that contained swabs from a patient suffering from a peculiar pneumonia sweeping China’s central city of Wuhan. But little did Zhang know that that box would also unleash a vicious squall of blame and geopolitical acrimony worthy of Pandora herself....
Source: TIME: Health - August 25, 2020 Category: Consumer Health News Authors: Charlie Campbell / Shanghai Tags: Uncategorized COVID-19 overnight Source Type: news

Exclusive: The Chinese Scientist Who Sequenced the First COVID-19 Genome Speaks Out About the Controversies Surrounding His Work
Over the past few years, Professor Zhang Yongzhen has made it his business to sequence thousands of previously unknown viruses. But he knew straight away that this one was particularly nasty. It was about 1:30 p.m. on Jan. 3 that a metal box arrived at the drab, beige buildings that house the Shanghai Public Health Clinical Center. Inside was a test tube packed in dry ice that contained swabs from a patient suffering from a peculiar pneumonia sweeping China’s central city of Wuhan. But little did Zhang know that that box would also unleash a vicious squall of blame and geopolitical acrimony worthy of Pandora herself....
Source: TIME: Science - August 25, 2020 Category: Science Authors: Charlie Campbell / Shanghai Tags: Uncategorized COVID-19 overnight Source Type: news

Exclusive: The Chinese Scientist Who Sequenced the First COVID-19 Genome Speaks Out About the Controversies Surrounding His Work
Over the past few years, Professor Zhang Yongzhen has made it his business to sequence thousands of previously unknown viruses. But he knew straight away that this one was particularly nasty. It was about 1:30 p.m. on Jan. 3 that a metal box arrived at the drab, beige buildings that house the Shanghai Public Health Clinical Center. Inside was a test tube packed in dry ice that contained swabs from a patient suffering from a peculiar pneumonia sweeping China’s central city of Wuhan. But little did Zhang know that that box would also unleash a vicious squall of blame and geopolitical acrimony worthy of Pandora herself....
Source: TIME: Health - August 25, 2020 Category: Consumer Health News Authors: Charlie Campbell / Shanghai Tags: Uncategorized COVID-19 overnight Source Type: news

How Convalescent Plasma Could Help Fight COVID-19
The last time most of us gave any thought to antibodies was probably in high school biology, but we’re getting a crash refresher course thanks to COVID-19. They are, after all, the key to our best defenses against SARS-CoV-2, the virus that’s caused the global pandemic. People who have been infected likely rely on antibodies to recover, and antibodies are what vaccines are designed to produce. Or at least that’s what infectious-disease and public-health experts assume for now. Because SARS-CoV-2 is such a new virus, even the world’s best authorities aren’t yet sure what it will take to build p...
Source: TIME: Health - August 24, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Leading in Time of COVID: A True Test of Leadership
By Folake OlayinkaAug 15 2020 (IPS) In 1918, the Spanish Flu, a deadly influenza caused by the H1N1 virus, decimated the world. Over the course of four successive waves, it infected 500 million people, about a third of the world’s population at the time, resulting in 50 million deaths. More recently between 2014 and mid-2016 , the Ebola virus epidemic was the most widespread outbreak of Ebola virus disease in history—causing devastating  loss of life and socioeconomic disruption in the West Africa region, mainly in Guinea, Liberia and Sierra Leone. These outbreaks, as well as SARS and MERS, each have ...
Source: IPS Inter Press Service - Health - August 15, 2020 Category: International Medicine & Public Health Authors: Folake Olayinka Tags: Democracy Headlines Health Source Type: news

Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
New Brunswick, N.J., August 05, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA). The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of th...
Source: Johnson and Johnson - August 5, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Religion & the Pandemic: A Call Beyond the Here & Now
Religions for Peace Interreligious Council of Albania distributing Covid relief supplies from the Multi-religious Humanitarian Fund. Credit: Erzen CarjaBy Prof. Azza KaramNEW YORK, Aug 4 2020 (IPS) — I have never been interested in religion or spirituality before, but I found myself tuning in to all sorts of on-line religion and spirituality related forums “in search of something.” These are the words of a 30-something single young, middle class man (born into a Protestant-Catholic family background) in a European country. The latter is known more for turning several churches into museums or shopping ce...
Source: IPS Inter Press Service - Health - August 4, 2020 Category: International Medicine & Public Health Authors: Azza Karam Tags: Civil Society Featured Global Headlines Health Human Rights Humanitarian Emergencies Inequity Religion TerraViva United Nations Source Type: news

Dr. Anthony Fauci Expresses ‘Cautious’ Optimism That COVID-19 Vaccine Will Be Available to Americans in 2021
(WASHINGTON) — Once a coronavirus vaccine is approved as safe and effective, Americans should have widespread access within a reasonable time, Dr. Anthony Fauci assured lawmakers Friday. Appearing before a House panel investigating the nation’s response to the pandemic, Fauci expressed “cautious” optimism that a vaccine would be available, particularly by next year. “I believe, ultimately, over a period of time in 2021, that Americans will be able to get it,” Fauci said, referring to the vaccine. There will be a priority list for who gets early vaccinations. “I don’t think we...
Source: TIME: Health - July 31, 2020 Category: Consumer Health News Tags: Uncategorized Congress COVID-19 News Desk wire Source Type: news

Inside the Global Quest to Trace the Origins of COVID-19 —and Predict Where It Will Go Next
It wasn’t greed, or curiosity, that made Li Rusheng grab his shotgun and enter Shitou Cave. It was about survival. During Mao-era collectivization of the early 1970s, food was so scarce in the emerald valleys of southwestern China’s Yunnan province that farmers like Li could expect to eat meat only once a year–if they were lucky. So, craving protein, Li and his friends would sneak into the cave to hunt the creatures they could hear squeaking and fluttering inside: bats. Li would creep into the gloom and fire blindly at the vaulted ceiling, picking up any quarry that fell to the ground, while his companion...
Source: TIME: Health - July 23, 2020 Category: Consumer Health News Authors: Charlie Campbell/ Yuxi, Yunnan and Alice Park Tags: Uncategorized COVID-19 feature Magazine Source Type: news

Report: Members of Russia ’s ‘Business and Political Elite’ Have Been Receiving Experimental COVID-19 Vaccine
(Bloomberg) — Scores of Russia’s business and political elite have been given early access to an experimental vaccine against COVID-19, according to people familiar with the effort, as the country races to be among the first to develop an inoculation. Top executives at companies including aluminum giant United Co. Rusal, as well as billionaire tycoons and government officials began getting shots developed by the state-run Gamaleya Institute in Moscow as early as April, the people said. They declined to be identified as the information isn’t public. The Gamaleya vaccine, financed by the state-run Russian D...
Source: TIME: Health - July 20, 2020 Category: Consumer Health News Authors: Stepan Kravchenko, Yuliya Fedorinova and Ilya Arkhipov / Bloomberg Tags: Uncategorized COVID-19 News Desk russia wire Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

UN Chief Warns of Deadly Germs as Potential Bioterrorist Weapons
Credit: United NationsBy Thalif DeenUNITED NATIONS, Jul 8 2020 (IPS) The coronavirus—which has claimed the lives of over 538,000 people and infected more than 11.6 million worldwide—has destabilized virtually every facet of human life ever since its outbreak in late December. Providing a grim economic scenario of the devastation caused by the pandemic– including rising poverty, hunger and unemployment– UN Secretary-General Antonio Guterres warned last week of the possibility of an even worse disaster: the risks of bioterrorist attacks deploying deadly germs. He said it has already shown some of the...
Source: IPS Inter Press Service - Health - July 8, 2020 Category: International Medicine & Public Health Authors: Thalif Deen Tags: Armed Conflicts Featured Global Global Geopolitics Global Governance Headlines Health IPS UN: Inside the Glasshouse Peace TerraViva United Nations Source Type: news

'I'm cautiously optimistic': Imperial's Robin Shattock on his coronavirus vaccine
Team is using new approach that could be cheap and scalable and become the norm within five yearsProf Robin Shattock would have liked slightly longer to develop the revolutionary approach to vaccines that he is pretty sure will not only save lives in the Covid-19 pandemic but become the norm for vaccine development within five years.His team at Imperial College were working on Ebola and Lassa fever vaccines using new technology but had not got as far as human trials when a novel coronavirus started to kill thousands of people in Wuhan, China.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 3, 2020 Category: Science Authors: Sarah Boseley Health editor Tags: Vaccines and immunisation Coronavirus outbreak Medical research Health Science Society Source Type: news

Johnson & Johnson Announces European Commission Approval for Janssen ’s Preventive Ebola Vaccine
Discussions with the U.S. Food and Drug Administration (FDA) have taken place to define the required data set for filing US licensure. About Janssen’s Ebola Vaccine Regimen The Janssen preventive Ebola vaccine regimen, Ad26.ZEBOV and MVA-BN-Filo, utilizes a non-replicating viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors carry the genetic code of several Ebola virus proteins in order to trigger an immune response.Janssen’s vac...
Source: Johnson and Johnson - July 1, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

How Deforestation Helps Deadly Viruses Jump from Animals to Humans
This article is republished from The Conversation under a Creative Commons license. Read the original article. The post How Deforestation Helps Deadly Viruses Jump from Animals to Humans appeared first on Inter Press Service. (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - June 26, 2020 Category: International Medicine & Public Health Authors: External Source Tags: Environment Global Headlines Health TerraViva United Nations Source Type: news

The U.S. Government's Push For Coronavirus Vaccine 'Warp Speed' Faces Potential Black Hole Of Red Tape And Universe Of Unknowns
Dr. Stephen Thomas, who helped develop vaccine candidates for diseases such as Ebola, Zika and MERS, discusses the challenges involved in accelerating development during a pandemic. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - June 16, 2020 Category: Pharmaceuticals Authors: Stephen Thomas, Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science Business /business Policy /policy Editors' Pick editors-pick Decision Maker decision-maker Coronavirus Source Type: news

New Report: 1,200+ Incidents of Violence Against Health Care in 2019
This article was originally published by theSafeguarding Health in Conflict Coalition. (Source: IntraHealth International)
Source: IntraHealth International - June 11, 2020 Category: International Medicine & Public Health Authors: cbishopp Tags: Safeguarding Health in Conflict Coalition Global health security Health Workers Source Type: news

What is lost in the smoke of COVID-19
Devyn Holliday, Research Officer, Economic, Youth & Sustainable Development Directorate   This blog is part of the seminar series on ‘The Economics of COVID-19’.By Devyn HollidayJun 10 2020 (IPS-Partners) When countries shuttered their shops, closed their markets, and cordoned off places of gathering to help ward off the coronavirus, they did so out of immediate concern for the health and wellbeing of their citizens. However, as these measures endure the virus is no longer the sole threat to the health and wellbeing of citizens. People across the globe are facing mounting threats to their wellbeing ...
Source: IPS Inter Press Service - Health - June 10, 2020 Category: International Medicine & Public Health Authors: Devyn Holliday Tags: Economy & Trade Health Labour Source Type: news

Melinda Gates Lays Out Her Biggest Concern For the Next Phase of the COVID-19 Pandemic
From 2018-2019, the Bill and Melinda Gates Foundation gave more money to the World Health Organization than any entity except the U.S. government. With President Donald Trump cutting ties to the international health agency in the midst of the COVID-19 pandemic, the Gates Foundation’s work has come into sharper relief than ever. Co-chair Bill Gates announced at the Global Vaccine Summit on June 4 that it will give $1.6 billion over five years to the Vaccine Alliance (GAVI), to help ensure that people around the world have access to vaccines, regardless of income. The Gates Foundation in 1999 pledged $750 million to he...
Source: TIME: Health - June 4, 2020 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized COVID-19 Source Type: news

Africa: Ebola, Hydroxychloroquine, COVID-19 – WHO Tackles a World of Health Challenges
[allAfrica] Washington, DC -Almost 50 responders from the World Health Organization (WHO) and its partners arrived today in Mbandaka in the Democratic Republic of Congo (DRC), along with 3600 doses of Ebola vaccine and 2000 cartridges for lab testing, WHO Director-General Dr. Tedros Adhanom Ghebreyesus told media in an online briefing. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - June 4, 2020 Category: African Health Source Type: news

COVID 19 – Conspiracy or Apocalypse? – Part I
By Daud Khan and Leila Yasmine KhanAMSTERDAM/ROME, Jun 1 2020 (IPS) As the COVID-19 virus spread rapidly around the globe, so did various theories about what caused the pandemic. According to the standard scientific theory, the virus probably originated in bats and then crossed over to humans, probably via another intermediate host. It then spread rapidly across the globe, piggybacking on the international travel network. While the mainstream scientific theory sufficed for some, a large number of people saw the pandemic as the work of cold-hearted military or industrial strategists. An equally large number of people saw it...
Source: IPS Inter Press Service - Health - June 1, 2020 Category: International Medicine & Public Health Authors: Daud Khan and Leila Yasmine Khan Tags: Global Headlines Health Source Type: news

Johnson & Johnson Receives Positive CHMP Opinion for Janssen ’s Investigational Preventive Ebola Vaccine Regimen
Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order...
Source: Johnson and Johnson - May 29, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

European agency panel recommends approval of J & J's Ebola vaccine
A panel of the European health regulator on Friday recommended approving Johnson& Johnson's two-dose experimental vaccine for Ebola in the European Union. (Source: Reuters: Health)
Source: Reuters: Health - May 29, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

How Remdesivir Works to Fight COVID-19 Inside the Body
On May 1, the U.S Food and Drug Administration issued an emergency-use authorization of remdesivir, an experimental anti-viral drug. With this clearance, doctors in the U.S. are now allowed to use the drug to treat patients with severe cases of COVID-19. Remdesivir isn’t new. It was initially developed to treat Ebola and was also tested in the lab against SARS and MERS—two other coronaviruses that infect humans much like the virus that causes COVID-19. It never made it to the approval stage for those uses, but over the last four months, scientists desperate for options to help mitigate the coronavirus pandemic ...
Source: TIME: Science - May 21, 2020 Category: Science Authors: Emily Barone and Lon Tweeten Tags: Uncategorized COVID-19 Source Type: news

How Remdesivir Works to Fight COVID-19 Inside the Body
On May 1, the U.S Food and Drug Administration issued an emergency-use authorization of remdesivir, an experimental anti-viral drug. With this clearance, doctors in the U.S. are now allowed to use the drug to treat patients with severe cases of COVID-19. Remdesivir isn’t new. It was initially developed to treat Ebola and was also tested in the lab against SARS and MERS—two other coronaviruses that infect humans much like the virus that causes COVID-19. It never made it to the approval stage for those uses, but over the last four months, scientists desperate for options to help mitigate the coronavirus pandemic ...
Source: TIME: Health - May 21, 2020 Category: Consumer Health News Authors: Emily Barone and Lon Tweeten Tags: Uncategorized COVID-19 Source Type: news

The Scientist Behind Some of the World ’s Best Coronavirus Images
From her laboratory in the far western reaches of Montana, Elizabeth Fischer is trying to help people see what they’re up against in COVID-19. Over the past three decades, Fischer, 58, and her team at the Rocky Mountain Laboratories, part of the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases, have captured and created some of the more dramatic images of the world’s most dangerous pathogens. “I like to get images out there to try to convey that this is an entity, to try to demystify it, so this is something more tangible for people,” says Fischer, on...
Source: TIME: Health - May 20, 2020 Category: Consumer Health News Authors: Markian Hawryluk / Kaiser Health News Tags: Uncategorized COVID-19 Source Type: news

The Scientist Behind Some of the World ’s Best Coronavirus Images
From her laboratory in the far western reaches of Montana, Elizabeth Fischer is trying to help people see what they’re up against in COVID-19. Over the past three decades, Fischer, 58, and her team at the Rocky Mountain Laboratories, part of the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases, have captured and created some of the more dramatic images of the world’s most dangerous pathogens. “I like to get images out there to try to convey that this is an entity, to try to demystify it, so this is something more tangible for people,” says Fischer, on...
Source: TIME: Science - May 20, 2020 Category: Science Authors: Markian Hawryluk / Kaiser Health News Tags: Uncategorized COVID-19 Source Type: news

US inroads to better Ebola vaccine
(Flinders University) As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses. In the latest collaboration with US partners, a vaccine turbocharger called Advax ™ adjuvant, was combined with a synthetic protein against Ebola developed by the United States Army Medical Research Institute of Infectious Disease (USAMRIID). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2020 Category: International Medicine & Public Health Source Type: news

Ebola virus disease – Democratic Republic of the Congo
From 6 to 12 May 2020, no new cases of Ebola virus disease (EVD) have been reported from North Kivu Province, Democratic Republic of the Congo (Figure 1). Since the resurgence of the outbreak on 10 April 2020, seven confirmed cases have been reported from Kasanga, Malepe and Kanzulinzuli Health Areas in Beni Health Zone. Of these, one is receiving care at the Beni Ebola treatment centre (ETC), one who was receiving care at the ETC recovered and was discharged, and one remains in the community, 35 days after symptom onset. Efforts to locate this individual are being undertaken to test and provide care for this person. Four ...
Source: WHO Disease Outbreaks - May 14, 2020 Category: Infectious Diseases Tags: news Source Type: news

How Pandemics End
An infectious outbreak can conclude in more ways than one, historians say. But for whom does it end, and who gets to decide? (Source: NYT Health)
Source: NYT Health - May 10, 2020 Category: Consumer Health News Authors: Gina Kolata Tags: Epidemics Coronavirus (2019-nCoV) Plague Smallpox Ebola Virus Influenza Epidemic (1918-19) Rats Antibiotics Bubonic Plague Fleas Microbiology Deaths (Fatalities) Vaccination and Immunization your-feed-science your-feed-health Source Type: news

Why Infectious Diseases Like COVID-19 Make Science Move So Fast
This article is part of #TIME100Talks: Finding Hope, a special series featuring leaders across different fields sharing their ideas for navigating the pandemic. Want more? Sign up for access to more virtual events, including live conversations with influential newsmakers. (Source: TIME: Health)
Source: TIME: Health - May 8, 2020 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized COVID-19 TIME 100 TIME100 Talks video Source Type: news

The Baltimore Bioterrorism Expert Who Inspired South Korea ’s COVID-19 Response
On Oct. 2, 2001, a 62-year-old photojournalist named Bob Stevens became the first victim of a coordinated series of anthrax attacks to be admitted to hospital. Stevens inhaled the deadly pathogen after opening one of several letters laced with anthrax spores which were mailed to the offices of prominent senators and media outlets across the U.S. Over the next seven weeks, he and four others would die as a result of their exposure. For a shell-shocked nation still reeling from the single deadliest terrorist attack in human history on September 11, it was a disturbing realization that there was a new wave of challenges to Am...
Source: TIME: Health - May 6, 2020 Category: Consumer Health News Authors: David Cox Tags: Uncategorized COVID-19 Source Type: news

Polio, Measles Outbreaks ‘Inevitable’, Say Vaccine Experts
A young boy in Pakistan receives an oral polio vaccine (OPV). Credit: Ashfaq Yusufzai/IPSBy Laura MackenzieMay 6 2020 (IPS) Interruptions to vaccination programmes caused by the COVID-19 pandemic could result in new waves of measles or polio outbreaks, health experts warn. A growing number of one-off immunisation campaigns and national routine vaccine introductions are being delayed amid social distancing and other measures to curb the spread of SARS-CoV-2, leaving millions unprotected. With both preventive campaigns and routine immunisations impacted, “we’ll have an increasing number of children who will becom...
Source: IPS Inter Press Service - Health - May 6, 2020 Category: International Medicine & Public Health Authors: Laura Mackenzie Tags: Global Headlines Health TerraViva United Nations Source Type: news

Global Impact of New Corona Virus and Population Issues
By Osamu KusumotoTOKYO, May 5 2020 (IPS) The new coronavirus (COVID-19) continues to wreak havoc across the world, as the number of infections and deaths rapidly rise. It has the potential to infect anybody regardless of age or gender. There are grave concerns that the economic fallout from COVID-19 may be comparable to that of the Great Depression. According to Johns Hopkins Coronavirus Resource Center, there are 2,064,668 confirmed cases of COVID-19 and 137,124 deaths due to SARS-CoV-2 (the virus causing COVID-19). In Japan as of noon April 15, there were 8,100 cases of COVID-19 , 119 deaths, and 901 patients discharged ...
Source: IPS Inter Press Service - Health - May 5, 2020 Category: International Medicine & Public Health Authors: Osamu Kusumoto Tags: Asia-Pacific Economy & Trade Global Headlines Health Humanitarian Emergencies Poverty & SDGs Source Type: news

Coronavirus: With pressure growing, global race for a vaccine intensifies
Some experts say the more immediately promising field might be the development of treatments to speed recovery from Covid-19, an approach that has generated some optimism in the last week through initially encouraging research results on remdesivir, an antiviral drug previously tried in fighting Ebola. (Source: The Economic Times)
Source: The Economic Times - May 3, 2020 Category: Consumer Health News Source Type: news

Ebola virus disease – Democratic Republic of the Congo
From 22 to 28 April 2020, one new confirmed case of Ebola virus disease (EVD) was reported from Beni Health Zone in North Kivu Province, Democratic Republic of the Congo (Figure 1). This person was listed as a contact of a confirmed case, a family member who was reported on 17 April. The person was vaccinated on 20 April and was followed by the contact tracing team, though not on a regular basis due to insecurity. Since the resurgence of the outbreak on 10 April 2020, seven confirmed cases have been reported, all from Beni Health Zone. Of these, one is receiving care at the Beni Ebola treatment centre (ETC), one who was re...
Source: WHO Disease Outbreaks - April 30, 2020 Category: Infectious Diseases Tags: news Source Type: news

Statement of Support on Access to New COVID-19 Tools
Johnson & Johnson fully endorses the goals of the Global Collaboration to Accelerate Development, Production and Equitable Access to New COVID-19 Tools. As the largest and most comprehensive healthcare company in the world, Johnson & Johnson has been at the forefront of public health challenges, from antibiotics for TB to treatments for HIV and other infectious diseases and developing vaccines for HIV, Ebola, Zika, and much more. We began working on a vaccine for COVID-19 the moment the sequence was announced and recently announced the selection of a lead COVID-19 vaccine candidate. We are accelerating our research...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Corporate Source Type: news

Meet Violet, the Robot That Can Kill the COVID-19 Virus
In just a few months, the COVID-19 pandemic has crossed borders and oceans, killing thousands, sickening millions, and forcing millions more to reckon with the economic and personal chaos of closures and lockdowns. Yet as the global infection count rises, the crisis has also given rise to acts of ingenuity. The pandemic has set off a global race for both an effective vaccine and for the accurate, rapid-response tests that will be necessary before workplaces can safely reopen. Vaccines and tests are essential, but they’re not the only front on which to combat the virus. In the face of an urgent threat, scientists have...
Source: TIME: Health - April 24, 2020 Category: Consumer Health News Authors: Corinne Purtill Tags: Uncategorized COVID-19 Source Type: news

Meet Violet, the Robot That Can Kill the COVID-19 Virus
In just a few months, the COVID-19 pandemic has crossed borders and oceans, killing thousands, sickening millions, and forcing millions more to reckon with the economic and personal chaos of closures and lockdowns. Yet as the global infection count rises, the crisis has also given rise to acts of ingenuity. The pandemic has set off a global race for both an effective vaccine and for the accurate, rapid-response tests that will be necessary before workplaces can safely reopen. Vaccines and tests are essential, but they’re not the only front on which to combat the virus. In the face of an urgent threat, scientists have...
Source: TIME: Science - April 24, 2020 Category: Science Authors: Corinne Purtill Tags: Uncategorized COVID-19 Source Type: news

Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company ’s Goal to Supply More Than One Billion Vaccine Doses Globally
NEW BRUNSWICK, N.J., April 23, 2020 - Johnson & Johnson (the Company) (NYSE: JNJ) today announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to support the manufacturing of its lead investigational COVID-19 vaccine candidate. This is the first in a series of prospective global collaboration agreements designed to accelerate manufacturing of Johnson & Johnson’s COVID-19 vaccine candidate, and further the Company’s goal to supply more than one billion doses of the vaccine globally. Paul Stoffels, M.D., Vice Chairman of the Executiv...
Source: Johnson and Johnson - April 24, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

What is the Ebola Virus?
Source: Council on Foreign Relations. Published: 4/20/2020. This resource, updated on April 20, 2020, provides background information about the Ebola virus, where it has occurred, and how it is contained. It discusses how response partners have continued to struggle to control the disease, despite the use of an experimental vaccine, as a new outbreak in the Democratic Republic of the Congo in 2018 grew to become the second largest ever. (Text) (Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health)
Source: Disaster Lit: Resource Guide for Disaster Medicine and Public Health - April 20, 2020 Category: International Medicine & Public Health Source Type: news

New universal Ebola vaccine may fight all four virus species that infect humans
(Cincinnati Children's Hospital Medical Center) Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize all four species of these deadly viruses infecting people in recent outbreaks, mainly in Africa. Although still in early preclinical testing, researchers report in the Journal of Virology that their data indicate that the prospective vaccine has potential to be a stand-alone protection from Ebola. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2020 Category: Infectious Diseases Source Type: news

Building a bridge to a COVID-19 vaccine
Regeneron has shared high hopes for its two candidates in the fight against COVID-19 on the first day of the four-day eyeforpharma Philadelphia virtual event.  George Yancopolous, President and Chief Scientific Officer at Regeneron, revealed that the company expected to have a good idea of the prospects for Kevzara, one of the two therapies it is hoping will be effective in fighting the virus, within a month. Regeneron is currently conducting a combined phase 2/3 adaptive trial for Kevzara. “We could be one to two weeks, at most a month away from knowing whether this is really making a difference or not,&r...
Source: EyeForPharma - April 15, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news